ACBI3

ACBI3 is an investigational small-molecule PROTAC degrader that eliminates oncogenic KRAS protein rather than merely inhibiting it. Developed jointly by Boehringer Ingelheim and the University of Dundee, it recruits the VHL E3 ubiquitin ligase to KRAS and rapidly degrades 13 of the 17 most common KRAS mutants as well as wild-type KRAS, while sparing HRAS and NRAS. The compound was described in a 2024 Science paper and distributed freely to researchers through the Boehringer Ingelheim opnMe portal, but it has not yet been evaluated in patients. Its degradation-based mechanism produces more potent and more durable MAPK pathway suppression than non-degrading KRAS inhibitors in preclinical models. KRAS mutations occur in 17 to 25 percent of all cancers, so a pan-mutant degrader addresses the majority of KRAS-driven tumours that approved mutation-specific inhibitors cannot reach.ACBI3 是一种在研小分子 PROTAC 降解剂，它消除致癌 KRAS 蛋白而非仅仅抑制其功能。该化合物由勃林格殷格翰与邓迪大学联合开发，将 VHL E3 泛素连接酶募集至 KRAS，快速降解 17 种最常见 KRAS 突变体中的 13 种以及野生型 KRAS，同时不影响 HRAS 与 NRAS。该化合物在 2024 年的一篇《科学》论文中描述，并通过勃林格殷格翰 opnMe 门户向研究者免费开放，但尚未在患者中评估。在临床前模型中，其基于降解的机制比非降解型 KRAS 抑制剂产生更强效、更持久的 MAPK 通路抑制。KRAS 突变发生于 17% 至 25% 的癌症中，因此泛突变降解剂覆盖了已批准突变特异性抑制剂无法触及的大多数 KRAS 驱动肿瘤。

History and development

• KRAS is the most frequently mutated oncogene in human cancer, with mutations in roughly 17 to 25 percent of all malignancies, yet approved targeted therapies address only the G12C mutation and leave more than half of KRAS-driven patients without a targeted option. The Dundee Centre for Targeted Protein Degradation and Boehringer Ingelheim therefore set out to design degraders covering as wide a range of oncogenic KRAS mutations as possible instead of inhibitors. The starting point was BI-2865, a non-covalent small-molecule inhibitor capable of inhibiting most KRAS mutants, whose SIIP binding motif was retained as the KRAS-binding prong. To this were added a linker and the established binding motif of the von Hippel-Lindau (VHL) E3 ligase as the recruiting prong, and the resulting compounds were optimized for stability and durability of the VHL-PROTAC-KRAS ternary complex.KRAS 是人类癌症中最常突变的致癌基因，约 17% 至 25% 的恶性肿瘤携带其突变，但已批准的靶向治疗仅覆盖 G12C 突变，过半 KRAS 驱动患者没有靶向选择。邓迪大学靶向蛋白降解中心与勃林格殷格翰因此着手设计覆盖尽可能广的致癌 KRAS 突变范围的降解剂，而非抑制剂。起点是 BI-2865，一种可抑制多数 KRAS 突变体的非共价小分子抑制剂，其 SIIP 结合基序被保留为 KRAS 结合端，再连接上连接子与冯希佩尔林道（VHL）E3 连接酶的成熟结合基序作为募集端，随后对化合物进行优化以获得稳定的 VHL-PROTAC-KRAS 三元复合物。
• A key step was co-crystallizing the three components KRAS, the PROTAC and VHL, which let the team visualize the ternary complex at atomic resolution by X-ray crystallography and then improve degrader activity step by step through rational design. The resulting compound ACBI3 was reported in Science on 20 September 2024 by a team co-led by Johannes Popow, Christiane Kofink and Andreas Gollner at Boehringer Ingelheim in Vienna and William Farnaby at Dundee, with Alessio Ciulli and Peter Ettmayer as co-corresponding authors. Boehringer Ingelheim has made ACBI3 freely available to the scientific community through its opnMe open-science portal without strings attached, and the compound is now catalogued as a chemical probe with a documented negative control. As of the latest reviews, ACBI3 has not yet been evaluated in patients, and IND-enabling studies including extended efficacy, resistance, toxicology and GMP production remain ahead.关键一步是对 KRAS、PROTAC 与 VHL 三组分进行共结晶，使团队得以通过 X 射线晶体学在原子分辨率上观察三元复合物，再通过理性设计逐步提升降解剂活性。所得化合物 ACBI3 于 2024 年 9 月 20 日登上《科学》，由勃林格殷格翰维也纳团队的 Johannes Popow、Christiane Kofink、Andreas Gollner 与邓迪大学的 William Farnaby 共同领导完成，Alessio Ciulli 与 Peter Ettmayer 为共同通讯作者。勃林格殷格翰已通过其 opnMe 开放科学门户无条件向科学界免费提供 ACBI3，该化合物现已被收录为具有明确阴性对照的化学探针。截至最新综述，ACBI3 尚未在患者中评估，包括延长疗效、耐药、毒理学与 GMP 生产在内的 IND 支持性研究仍在前面。^[1]
• The degrader concept itself dates to 2001, when Sakamoto and colleagues described chimeric molecules that recruit a target protein to an SCF ubiquitin ligase complex for destruction, work that spawned the PROTAC field and its later clinical translation. Two decades on, the approach had matured enough to be turned on KRAS, a target long considered undruggable until the discovery of a pocket beneath the switch II region enabled small-molecule inhibition. The first KRAS inhibitor, the covalent G12C agent sotorasib, received accelerated approval in the United States in May 2021 for previously treated non-small cell lung cancer, and the covalent inhibitor adagrasib followed in June 2022. Degradation was proposed as the next conceptual step beyond those mutation-specific inhibitors.降解剂概念本身可追溯至 2001 年，当时 Sakamoto 及其同事描述了将靶蛋白募集至 SCF 泛素连接酶复合物以摧毁之的嵌合分子，这项工作催生了 PROTAC 领域及其后的临床转化。二十年后，该方法已足够成熟，得以转向 KRAS 这一长期被视为不可成药的靶点——直到（switch II）区域下方口袋的发现才使小分子抑制成为可能。首个 KRAS 抑制剂、共价 G12C 药物（sotorasib）于 2021 年 5 月在美国获加速批准用于经治非小细胞肺癌，共价抑制剂（adagrasib）随后于 2022 年 6 月获批。降解被视为超越这些突变特异性抑制剂的下一个概念性步骤。
• ACBI3 belongs to a second generation of KRAS agents that tries to address alleles beyond G12C, where the medical need is largest: G12D and G12V are the most prevalent oncogenic KRAS alleles overall, and G12D alone dominates pancreatic ductal adenocarcinoma. Investigational competitors include the non-covalent G12D inhibitor MRTX1133, the pan-RAS inhibitor RMC-6236, and Boehringer Ingelheim's own pan-KRAS inhibitor BI-2493, a rigid analogue of BI-2865 described in 2025. Unlike those inhibitors, ACBI3 works by removing the protein, so it is not tied to a single allele's binding geometry. The pan-mutant coverage is the programme's defining claim.ACBI3 属于试图覆盖 G12C 之外突变型的第二代 KRAS 药物，而那里的医疗需求最大：G12D 与 G12V 是总体最常见的致癌 KRAS 等位基因，仅 G12D 即在胰腺导管腺癌中占主导。在研竞品包括非共价 G12D 抑制剂 MRTX1133、泛 RAS 抑制剂 RMC-6236，以及勃林格殷格翰自研的泛 KRAS 抑制剂 BI-2493（BI-2865 的刚性类似物，2025 年报道）。与这些抑制剂不同，ACBI3 通过移除蛋白起作用，因此不受单一等位基因结合几何的限制。泛突变覆盖是该项目的标志性主张。
• The work was a genuine two-site collaboration: the Vienna team ran the medicinal chemistry and the cellular degradation programmes, while the Dundee team contributed the biophysical and structural biology, including the ternary complex co-crystal structures that guided optimization. The division of labour reflected a longer-standing Dundee capability in targeted protein degradation, built around the Centre for Targeted Protein Degradation led by Alessio Ciulli. A bioRxiv preprint in October 2023 preceded the journal article by almost a year, and the final paper added the probe-quality control data. Coverage in a research-highlight review later placed the compound at the centre of the small-molecule KRAS degrader field.这是一项真正的双站点合作：维也纳团队负责药物化学与细胞降解项目，邓迪团队贡献生物物理与结构生物学，包括指导优化的三元复合物共晶结构。这一分工反映了邓迪在靶向蛋白降解方面更长期的积累，围绕 Alessio Ciulli 领导的靶向蛋白降解中心建设。2023 年 10 月的 bioRxiv 预印本比期刊论文早了近一年，最终论文补充了探针级对照数据。后续研究亮点综述的报道将该化合物置于小分子 KRAS 降解剂领域的中心位置。

Medical uses

• ACBI3 is a preclinical candidate with no approved use in any jurisdiction, and its intended role is the treatment of KRAS-mutant cancers such as pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer. In mouse xenograft models it produced clear antitumour activity: daily subcutaneous injection at 30 mg/kg for 14 consecutive days caused tumour regression in GP2d tumours carrying KRAS G12D, with a tumour growth inhibition rate of 127 percent and KRAS G12D levels falling to 44 percent of the untreated control. In the RKN model carrying KRAS G12V, intraperitoneal administration likewise induced tumour regression, at efficacy comparable to the pan-KRAS inhibitor BI-2493 given at 180 mg/kg daily.ACBI3 是临床前候选药物，未在任何司法管辖区获批，其拟定的用途是治疗 KRAS 突变癌症，如胰腺导管腺癌、结直肠癌与非小细胞肺癌。在小鼠移植瘤模型中它表现出明确的抗肿瘤活性：在携带 KRAS G12D 的 GP2d 肿瘤中，30 mg/kg 每日皮下注射连续 14 天引起肿瘤消退，肿瘤生长抑制率达 127%，瘤内 KRAS G12D 水平降至未处理对照的 44%。在携带 KRAS G12V 的 RKN 模型中，腹腔给药同样诱导肿瘤消退，疗效与每日 180 mg/kg 的泛 KRAS 抑制剂 BI-2493 相当。
• Because degradation removes the protein rather than occupying its active site, the approach is proposed to overcome or mitigate classic KRAS inhibitor resistance mechanisms such as KRAS amplification or secondary KRAS mutations. In cell assays the degrader outperformed non-degrading inhibitors by more than tenfold across GP2d, SW620 and NCI-H358 lines expressing KRAS G12D, G12V and G12C, induced G1/G0 cell-cycle arrest and maintained MAPK pathway suppression after treatment cessation. Across a panel of cancer cell lines the geometric mean IC50 was 478 nM in KRAS-mutant lines versus 8.3 micromolar in KRAS wild-type lines, indicating selective pressure on mutant-driven cells. Cells with GTP-hydrolysis-impaired KRAS Q61K were insensitive, marking a mutation-level limit of the approach.由于降解是移除蛋白而非占据其活性位点，该策略被认为可克服或缓解经典的 KRAS 抑制剂耐药机制，如 KRAS 扩增或继发性 KRAS 突变。在细胞实验中，该降解剂在表达 KRAS G12D、G12V 与 G12C 的 GP2d、SW620 与 NCI-H358 细胞系中比非降解抑制剂强效十倍以上，诱导 G1/G0 细胞周期阻滞，并在停药后仍维持 MAPK 通路抑制。在癌细胞系面板中，KRAS 突变系的几何平均 IC50 为 478 纳摩尔，而 KRAS 野生型系为 8.3 微摩尔，显示对突变驱动细胞的选择性压力。GTP 水解受损的 KRAS Q61K 细胞不敏感，标明了该方法在突变层面的局限。
• The clinical rationale for a pan-mutant agent is quantitative: G12C accounts for a minority of KRAS-driven disease, while G12D and G12V alleles are collectively more prevalent and dominate pancreatic cancer, the tumour type with the largest KRAS-driven share. A single degrader that covers 13 of the 17 most common alleles plus wild type could therefore treat a much larger population than any mutation-specific inhibitor. The wild-type coverage is a double-edged feature, since KRAS also supports normal tissue homeostasis, and the therapeutic window in patients remains untested. For now the compound serves as a research tool to study KRAS biology rather than as a therapy.泛突变药物的临床依据是量化层面的：G12C 仅占 KRAS 驱动疾病的少数，而 G12D 与 G12V 等位基因合计更常见，并在 KRAS 驱动占比最高的胰腺癌中占主导。覆盖 17 种最常见等位基因中 13 种再加野生型的单一降解剂，原则上可比任何突变特异性抑制剂治疗更大的人群。野生型覆盖是把双刃剑，因为 KRAS 也支持正常组织稳态，其在患者中的治疗窗尚未检验。目前该化合物用作研究 KRAS 生物学的研究工具，而非治疗药物。
• Combination strategies under discussion for KRAS degraders include pairing them with SOS1 or SHP2 inhibitors that block upstream activation, and with immune checkpoint blockade, since degradation releases antigen from dying tumour cells. Preclinical work on the DSP-7888 vaccine programme and on PROTAC-treated models has suggested that killing KRAS-mutant cells can increase their visibility to T cells, although no ACBI3 combination has been published. The compound's effect on the tumour microenvironment, including stromal and immune compartments, has not been characterized.KRAS 降解剂讨论中的联合策略包括与阻断上游激活的 SOS1 或 SHP2 抑制剂联用，以及与免疫检查点阻断联用，因为降解会从垂死肿瘤细胞释放抗原。DSP-7888 疫苗项目与 PROTAC 处理模型的临床前工作提示，杀伤 KRAS 突变细胞可提高其对 T 细胞的可见性，但尚无 ACBI3 联合方案发表。该化合物对肿瘤微环境（包括间质与免疫组分）的影响尚未表征。
• No dosing regimen exists for humans, and the preclinical record relies on parenteral administration in mice, which the original authors flag as a significant challenge for daily long-term use. The intended patient population, if the programme advances, would be previously treated patients with advanced KRAS-mutant solid tumours, a setting in which options are limited and response durations short. Biomarker selection would in principle be unnecessary because the degrader covers most alleles, though testing for KRAS mutation would still be required to exclude KRAS wild-type disease. The compound is not positioned for KRAS wild-type amplified tumours despite covering wild-type protein in vitro.不存在人体给药方案，临床前记录依赖小鼠肠外给药，原创作者指出这对每日长期使用是重大挑战。若项目推进，目标人群将是既往治疗的晚期 KRAS 突变实体瘤患者，这一情境下选择有限、缓解期短。原则上无需生物标志物筛选，因为降解剂覆盖多数等位基因，但仍需检测 KRAS 突变以排除野生型疾病。尽管该化合物在体外覆盖野生型蛋白，其定位不针对 KRAS 野生型扩增肿瘤。

Adverse effects

• No human adverse-effect data exist because ACBI3 has not entered clinical trials, so all tolerability evidence is preclinical. In the mouse efficacy studies the compound was systemically well tolerated, with no discernible impact on body weight during 14 days of dosing at 30 mg/kg. During the subcutaneous efficacy study, however, skin lesions were noted at the injection area, which prompted reformulation as a nanomilled suspension given intraperitoneally. The intraperitoneal route restored exposure above the predicted degradation concentration and was tolerated well on repeated dosing, illustrating that route and formulation, not the degrader mechanism, drove the local toxicity.由于 ACBI3 尚未进入临床试验，不存在人体不良反应数据，所有耐受性证据均来自临床前。在小鼠疗效研究中该化合物全身耐受良好，30 mg/kg 连续 14 天给药期间体重无可辨别影响。但在皮下给药疗效研究中观察到注射部位皮肤病变，因此改为纳米研磨混悬液腹腔给药。腹腔给药使暴露重回预测降解浓度阈值以上，且重复给药耐受良好，说明驱动局部毒性的是给药途径与处方而非降解机制本身。
• Selectivity data suggest a manageable therapeutic window: proteomic analysis covering more than 5,000 proteins showed KRAS among the most significantly downregulated proteins after treatment, with no notable change in HRAS or NRAS levels, reflecting isoform selectivity within the RAS family. Resistance liabilities specific to the PROTAC design are nevertheless anticipated, including loss of VHL E3 ligase expression and the poor solubility, permeability and bioavailability that accompany the dual-binding architecture. Expert reviewers of the chemical probe noted that high efflux could be mitigated with the inhibitor（zosuquidar）, a practical point for experimental use.选择性数据提示可掌控的治疗窗：覆盖 5000 多种蛋白的蛋白质组学分析显示，治疗后 KRAS 是下调最显著的蛋白之一，而 HRAS 或 NRAS 水平无明显变化，反映了 RAS 家族内的异构体选择性。但 PROTAC 设计特有的耐药风险仍可预期，包括 VHL E3 连接酶表达缺失，以及双结合架构伴随的溶解性、通透性与生物利用度不足。化学探针评审专家指出，高外排可用抑制剂（zosuquidar）缓解，这是实验应用中的实用要点。
• PROTAC degraders as a class can produce event-driven toxicities that inhibitors do not, because a single degrader molecule can trigger destruction of many target molecules and because E3 ligase engagement can have downstream effects on the ligase's other substrates. The negative control cis-ACBI3, which cannot engage VHL, provides the experimental separation between these two prongs and was itself tolerated in the reported studies. No formal toxicology programme, no maximal tolerated dose and no combination safety data have been published for ACBI3, so any human safety statement would be speculative. The probe dossier distributed with the compound asks users to treat tolerability as uncharacterized.PROTAC 降解剂作为一类药物可产生抑制剂不会出现的事件驱动毒性，因为单个降解剂分子可触发多个靶分子的摧毁，且 E3 连接酶接合可能对该连接酶的其他底物产生下游影响。无法接合 VHL 的阴性对照 cis-ACBI3 为区分这两个末端提供了实验手段，其在已报告研究中本身耐受良好。ACBI3 尚无正式毒理学项目、最大耐受剂量与联合安全性数据发表，因此任何人体安全性表述都是推测性的。随化合物分发的探针档案要求使用者将耐受性视为未表征。
• Because KRAS degradation also removes wild-type protein, on-target toxicity in normal regenerative tissues is a theoretical concern that the wild-type selectivity data only partly address: KRAS wild-type cell lines were roughly seventeenfold less sensitive than mutant lines, but they were not completely unaffected. Tissues with high KRAS-dependent turnover, such as the gut and the haematopoietic system, are the usual focus of KRAS programme safety monitoring. The reported mouse studies showed no body-weight loss, but 14 days of dosing is too short to reveal delayed marrow or gastrointestinal toxicity. No recovery or reversibility data have been published.由于 KRAS 降解同时移除野生型蛋白，正常再生组织的靶内毒性是一个理论关切，而野生型选择性数据只能部分回答：KRAS 野生型细胞系的敏感性约为突变系的十七分之一，但并非完全不受影响。KRAS 依赖性周转高的组织（如肠道与造血系统）是 KRAS 项目安全性监测的常规重点。已报告的小鼠研究未见体重下降，但 14 天给药太短，无法揭示延迟的骨髓或胃肠道毒性。尚无恢复性或可逆性数据发表。
• Radioligand-style dosimetry does not apply here, but the concept of a degradation threshold does: exposure must stay above the predicted in vivo degradation concentration of 281 nM for KRAS removal to continue, and the reported pharmacokinetics maintained that level for only about 6 hours after subcutaneous dosing. Below that threshold the compound behaves as a conventional inhibitor, so toxicity and efficacy are expected to track the same exposure window. Intermittent schedules that let KRAS resynthesize between doses could reduce cumulative toxicity but might also permit tumour re-growth, a trade-off the programme has not yet explored publicly.放射配体式的剂量学在此不适用，但降解阈值的概念适用：暴露必须维持在预测体内降解浓度 281 纳摩尔以上，KRAS 移除才能持续，而报告的药代动力学在皮下给药后仅维持该水平约 6 小时。低于该阈值时化合物表现为常规抑制剂，因此毒性与疗效预期跟踪同一暴露窗。让 KRAS 在剂量间重新合成的间歇方案可能降低累积毒性，但也可能允许肿瘤再生，这一权衡项目尚未公开探讨。

Contraindications and interactions

• No contraindications can be listed for a compound that has never been dosed in humans, and none are defined in the published preclinical record. The only formal control is experimental: the stereoisomer cis-ACBI3 serves as a negative control because it is deficient in VHL binding and therefore cannot degrade KRAS, although it still binds KRAS and acts as a non-covalent inhibitor. Any future clinical contraindications would have to await first-in-human studies. No food, beverage or drug interaction has been characterized.对于从未在人体给药的化合物无法列出禁忌，已发表的临床前记录中亦无定义。唯一正式的对照是实验性的：立体异构体 cis-ACBI3 因 VHL 结合缺陷而无法降解 KRAS，可作阴性对照，尽管它仍能结合 KRAS 并作为非共价抑制剂发挥作用。任何未来的临床禁忌都有待首次人体研究。尚无食物、饮料或药物相互作用被表征。
• The compound's metabolic route and enzyme dependence have not been publicly characterized, so cytochrome-mediated interactions cannot be predicted from the available data. Given its physicochemical profile, with a high calculated logP of about 5.5, hepatic metabolism and transporter-mediated disposition are the likely routes, but this remains inference rather than published fact. Users of the probe are advised to treat concomitant dosing with cytochrome modulators as an uncontrolled variable. The VHL-engaging end raises a theoretical interaction with proteasome inhibitors, which would block the degradation step downstream of ubiquitination.该化合物的代谢途径与酶依赖性尚未公开表征，因此无法从现有数据预测细胞色素介导的相互作用。鉴于其理化特征（计算 logP 约 5.5），肝代谢与转运体介导的处置是可能途径，但这仍是推断而非已发表事实。探针使用者被建议将细胞色素调节剂的合并给药视为不受控变量。其接合 VHL 的一端提出与蛋白酶体抑制剂的理论相互作用，后者将阻断泛素化下游的降解步骤。
• A second experimental consideration is the hook effect: at sufficiently high concentrations, PROTACs can form binary rather than ternary complexes, and degradation efficiency falls, an effect documented for several degraders and relevant to dosing design. For ACBI3 the cellular degradation concentrations of 2 to 7 nM sit well below the concentrations where hook effects typically appear, so the risk is manageable in vitro but must be re-checked in vivo. High concentrations also increase off-rate of the ternary complex, another reason dose selection cannot simply maximize exposure.第二个实验考量是钩子效应：在足够高浓度下，PROTAC 可形成二元而非三元复合物，降解效率下降，该效应已在多种降解剂中记录，与给药设计相关。对 ACBI3 而言，2 至 7 纳摩尔的细胞降解浓度远低于钩子效应通常出现的浓度，因此该风险在体外可掌控，但必须在体内重新核查。高浓度还会提高三元复合物的解离速率，这是剂量选择不能简单最大化暴露的另一原因。

Pharmacology

• ACBI3 works by forced proximity: one prong binds KRAS, the other recruits the VHL E3 ligase, and the resulting ternary complex positions the ligase to ubiquitinate KRAS and route it to the proteasome. Binding constants reported for the probe include a KRAS Kd of 6 nM, cellular degradation concentrations (DC50) of 2 to 7 nM and growth-inhibition IC50 values of 5 to 15 nM. Phosphoproteomic analysis showed the degrader produces a larger effect size than a matched non-degrading inhibitor, and cells treated with the degrader maintained MAPK pathway suppression after the compound was removed, unlike inhibitor-treated cells. The KRAS G12D level in treated tumours fell to 44 percent of control and did not rebound significantly over 24 hours despite a fivefold change in compound exposure, consistent with a pharmacodynamic effect outlasting the pharmacokinetic exposure.ACBI3 通过强制近距发挥作用：一端结合 KRAS，另一端募集 VHL E3 连接酶，形成的三元复合物将连接酶定位以泛素化 KRAS 并将其送至蛋白酶体。该探针报告的结合常数包括 KRAS Kd 6 纳摩尔、细胞降解浓度（DC50）2 至 7 纳摩尔与生长抑制 IC50 5 至 15 纳摩尔。磷酸化蛋白质组学分析显示，该降解剂比匹配的非降解抑制剂产生更大的效应量，且处理细胞在化合物移除后仍维持 MAPK 通路抑制，与抑制剂处理细胞不同。处理后肿瘤中 KRAS G12D 水平降至对照的 44%，且在 24 小时内尽管化合物暴露变化五倍也未显著回升，与药效学效应持续久于药代动力学暴露一致。
• The VHL recruitment prong exploits the normal substrate-recognition mechanism of the von Hippel-Lindau tumour suppressor, the substrate receptor of a cullin-2 E3 ligase complex that normally marks hydroxylated hypoxia-inducible factor alpha for destruction. By presenting a KRAS-binding group to the same ligase, the PROTAC redirects that degradation machinery to an oncoprotein it never sees in nature. The ternary complex is cooperative, meaning that binding of one prong improves affinity of the other, which is why compounds with modest binary affinities can still degrade efficiently. Cooperativity was the central parameter optimized during the linker screen.VHL 募集端利用了冯希佩尔林道肿瘤抑制因子的正常底物识别机制，该蛋白是 cullin-2 E3 连接酶复合物的底物受体，正常时给羟化缺氧诱导因子 α 打上摧毁标记。通过向同一连接酶呈递 KRAS 结合基团，PROTAC 把该降解机器改道到一个自然界中永远不会遇到的癌蛋白上。三元复合物具有协同性，即一端的结合改善另一端的亲和力，这就是为何二元亲和力平平的化合物仍能高效降解。协同性是连接子筛选期间优化的核心参数。
• KRAS itself is a small GTPase that cycles between active GTP-bound and inactive GDP-bound states under the control of SOS1-mediated nucleotide exchange, and it signals through RAF-MEK-ERK and PI3K pathways that drive proliferation and survival. Oncogenic mutations such as G12D and G12V lock the protein in its active state by impairing GTP hydrolysis, which is why the Q61K mutant that cannot hydrolyse GTP is insensitive to ACBI3 despite carrying a druggable switch II pocket. Removing the protein by degradation bypasses the nucleotide-state problem that makes KRAS so difficult to inhibit selectively. The downstream pathway suppression observed after treatment is the pharmacological readout of that removal.KRAS 本身是一种小分子 GTP 酶，在 SOS1 介导的核苷酸交换控制下于结合 GTP 的活性态与结合 GDP 的非活性态之间循环，并通过 RAF-MEK-ERK 与 PI3K 通路传递驱动增殖与存活的信号。G12D 与 G12V 等致癌突变通过损害 GTP 水解将蛋白锁定于活性态，这就是为何无法水解 GTP 的 Q61K 突变体虽携带可成药（switch II）口袋却对 ACBI3 不敏感。通过降解移除蛋白，绕开了使 KRAS 难以被选择性抑制的核苷酸状态问题。处理后观察到的下游通路抑制，正是这种移除的药理学读数。
• In vivo pharmacokinetics in mice show a short intravenous half-life of 0.67 hours at 2 mg/kg with systemic clearance of 39 mL per hour per kg, a steady-state volume of distribution of 1.6 L/kg and an AUC of 857 nmol/L per hour. After subcutaneous dosing at 30 mg/kg the peak plasma concentration reached 70 nM at 2 hours with an AUC of 9,040 nM per hour per litre, and the predicted in vivo degradation concentration of 281 nM was maintained for approximately 6 hours. Because exposure above that threshold persists, KRAS degradation continues even as plasma levels fall. The compound requires parenteral administration, which the original authors flag as a significant challenge for daily long-term use.小鼠体内药代动力学显示，2 mg/kg 静脉给药后半衰期 0.67 小时，系统清除率每小时每公斤 39 mL，稳态分布容积 1.6 L/kg，AUC 为每小时每升 857 纳摩尔。30 mg/kg 皮下给药后血浆峰浓度在 2 小时达 70 纳摩尔，AUC 为每小时每升 9040 纳摩尔，预测体内降解浓度 281 纳摩尔维持约 6 小时。由于暴露高于该阈值可持续，即使血浆水平下降，KRAS 降解仍继续。该化合物需要肠外给药，原创作者指出这对每日长期使用是重大挑战。
• Resynthesis kinetics matter for scheduling: KRAS protein has to be made anew between doses, and the observed 24-hour stability of the KRAS G12D drop implies that protein recovery lags drug clearance substantially. This lag is the pharmacokinetic-pharmacodynamic disconnect that distinguishes degraders from inhibitors and underlies the sustained pathway suppression after dosing stops. Whether the effect survives a dosing interval long enough for convenient administration is the key question the programme has yet to answer. No repeat-dose pharmacokinetic study has been published.再合成动力学对给药排程重要：KRAS 蛋白必须在剂量间重新合成，而观察到的 KRAS G12D 下降 24 小时稳定，意味着蛋白恢复显著滞后于药物清除。这一滞后正是区分降解剂与抑制剂的药代-药效脱节，也是停药后通路抑制持续的基础。该效应能否在长到便于给药的间隔后存续，是项目尚未回答的关键问题。尚无重复给药药代动力学研究发表。
• The breadth of allele coverage was mapped across the common KRAS variants, with 13 of the 17 most prevalent oncogenic alleles degraded efficiently together with wild-type KRAS. Selectivity within the RAS family was the counterweight: HRAS and NRAS were not degraded, limiting the risk of pan-RAS collapse that would be poorly tolerated. The four non-degraded alleles and the insensitive Q61K mutant define the boundaries of the pan-mutant claim and are the natural focus of follow-up optimization. Degradation efficiency varied across alleles, so pan-mutant coverage does not mean uniform potency.等位基因覆盖广度已在常见 KRAS 变异中测绘，17 种最普遍致癌等位基因中的 13 种与野生型 KRAS 一起被高效降解。RAS 家族内的选择性是制衡：HRAS 与 NRAS 不被降解，限制了难以耐受的泛 RAS 崩塌风险。四个未被降解的等位基因与不敏感的 Q61K 突变体划定了泛突变主张的边界，也是后续优化的天然焦点。降解效率在不同等位基因间有差异，因此泛突变覆盖并不意味着效价均一。

Chemistry

• ACBI3 has molecular formula C50H62N14O6S2 and molecular weight 1018.44 Da, with InChIKey DQRZNYPHOWVXPQ-YDUPODKQSA-N and CAS number 2938169-76-5. Its architecture combines the BI-2865-derived SIIP KRAS-binding motif, a linker and the VHL E3 ligase ligand, giving a molecule far larger and more complex than a classical inhibitor. The compound is registered in PubChem under CID 169449364, in ChemSpider under 129422922 and in ChEMBL under CHEMBL6195033, and its canonical SMILES are distributed with the chemical probe record. The high AlogP of about 5.5 and 20 hydrogen-bond acceptors underpin both its potency and its permeability limitations.ACBI3 分子式为 C50H62N14O6S2，分子量 1018.44 Da，InChIKey 为 DQRZNYPHOWVXPQ-YDUPODKQSA-N，CAS 号为 2938169-76-5。其架构组合了源自 BI-2865 的 SIIP KRAS 结合基序、连接子与 VHL E3 连接酶配体，分子远比经典抑制剂更大更复杂。该化合物在 PubChem 注册号为 CID 169449364，ChemSpider 为 129422922，ChEMBL 为 CHEMBL6195033，其规范 SMILES 随化学探针记录一同分发。约 5.5 的高 AlogP 与 20 个氢键受体同时决定了它的效价与通透性局限。
• The negative control cis-ACBI3 is a stereoisomer that displays deficient binding to VHL and hence cannot support KRAS degradation, while still binding KRAS as a non-covalent inhibitor, which makes it the matched control for separating degradation-driven from inhibition-driven effects. The co-crystal structure of the KRAS-PROTAC-VHL complex was central to the optimization, and the final compound was engineered for ternary complex stability and durability rather than for binary affinity alone. No salt form or prodrug version has been disclosed, and the clinical supply route would require new formulation work given the molecule's size.阴性对照 cis-ACBI3 是一种立体异构体，对 VHL 结合缺陷因而无法支持 KRAS 降解，但仍能结合 KRAS 作为非共价抑制剂，这使它成为区分降解驱动与抑制驱动效应的匹配对照。KRAS-PROTAC-VHL 复合物的共晶结构是优化核心，最终化合物的工程设计目标是三元复合物的稳定性与持久性，而非单纯的二元亲和力。尚未披露盐型或前药版本，且鉴于分子体积，临床供应路线需要新的处方开发工作。
• The VHL-binding prong is built on the established VH032-type ligand chemistry, in which a hydroxyproline-centred motif engages the von Hippel-Lindau substrate-binding pocket, and the linker screen compared alkyl and polyethylene-glycol options for cooperativity and exposure. Linker composition is the main handle for tuning the pharmacokinetics of PROTACs, and the polyethylene-glycol-type choices in this series traded solubility for exposure. The KRAS-binding prong retains the SIIP motif that occupies the switch II pocket, the same site addressed by the pan-KRAS inhibitor programme. No deuterated or otherwise modified analogue has been reported.VHL 结合端建立在成熟的 VH032 型配体化学之上，其中以羟脯氨酸为核心的基序接合冯希佩尔林道底物结合口袋，连接子筛选则比较了烷基与聚乙二醇类选项在协同性与暴露上的表现。连接子组成是调节 PROTAC 药代动力学的主要抓手，该系列中的聚乙二醇类选择以暴露换取溶解性。KRAS 结合端保留了占据（switch II）口袋的 SIIP 基序，与泛 KRAS 抑制剂项目针对同一位点。尚无氘代或其他修饰类似物的报道。
• As a bi-functional molecule, ACBI3 sits at the extreme end of the rule-of-five property space, and its molecular weight of 1018.44 Da is roughly triple that of sotorasib. The rule-of-five framework, designed for orally absorbed drugs, does not describe such compounds well, which is why the field measures degraders by cellular DC50 rather than by ligand-efficiency metrics. Solubility and permeability were improved during the campaign by the linker and formulation choices rather than by structural simplification. Whether an orally bioavailable KRAS degrader is achievable remains an open question for the field.作为双功能分子，ACBI3 处于五规则性质空间的最极端，其 1018.44 Da 的分子量约为（sotorasib）的三倍。为口服吸收药物设计的五规则框架不能很好描述此类化合物，这就是该领域以细胞 DC50 而非配体效率指标衡量降解剂的原因。溶解性与通透性的改善来自连接子与处方选择，而非结构简化。口服可及的 KRAS 降解剂能否实现，仍是该领域的开放问题。

Society and culture

• ACBI3 has no regulatory status in any country, does not appear on the WHO Model List of Essential Medicines and has no ATC code, which is standard for a preclinical probe. Its distribution through the opnMe portal is itself a notable policy choice, giving academic and industry laboratories string-free access to a tool compound for studying KRAS degradation. The compound has become a reference pan-KRAS degrader in the targeted protein degradation field, and its publication in Science placed KRAS degradation alongside molecular glues as a validated route for a target long considered undruggable. Public and scientific discussion has emphasized that degradation, unlike inhibition, could in principle address resistance driven by KRAS overexpression.ACBI3 在任何国家均无监管地位，未出现在 WHO 基本药物示范清单上，也没有 ATC 编码，这对临床前探针属标准情况。其通过 opnMe 门户分发本身就是值得注意的政策选择，使学术界与工业界实验室无条件获得研究 KRAS 降解的工具化合物。该化合物已成为靶向蛋白降解领域的参照性泛 KRAS 降解剂，其登上《科学》与分子胶并列，把 KRAS 降解确立为这一长期被视为不可成药靶点的已验证路径。公众与科学讨论强调，与抑制不同，降解原则上可应对由 KRAS 过表达驱动的耐药。
• Distribution as a chemical probe carries obligations: the opnMe record asks users to report data back, and the probe dossier includes the negative control cis-ACBI3, usage recommendations and the structural data needed to interpret results. Probe standards of this kind were developed by the structural genomics community to make tool compounds comparable across laboratories, and they have become the de facto quality bar for academic drug discovery. The Dundee centre that co-developed ACBI3 has been a reference point for probe practice since the BET bromodomain probes of the early 2010s. Boehringer Ingelheim's open-science programme has since released several tool compounds through the same portal.以化学探针身份分发附带义务：opnMe 记录要求使用者回传数据，探针档案包含阴性对照 cis-ACBI3、使用建议与解读结果所需的结构数据。此类探针标准由结构基因组学界开发，旨在使工具化合物在实验室间可比，并已成为学术药物发现的事实质量标杆。联合开发 ACBI3 的邓迪中心自 2010 年代初的 BET 溴结构域探针以来一直是探针实践的参照点。勃林格殷格翰的开放科学项目此后通过同一门户发布了多个工具化合物。
• Review coverage of the KRAS degrader field has treated ACBI3 as the compound that proved the concept, noting that its design was guided by biophysical and structural studies of ternary complexes rather than by empirical screening alone. The same reviews place it in a competitive landscape that includes academic degraders and company programmes from several pharmaceutical firms. The broader cultural significance lies in the shift of KRAS from the canonical undruggable target to a field with inhibitors, degraders and combination strategies in parallel development. That shift is now a standard case study in targeted protein degradation courses and reviews.KRAS 降解剂领域的综述把 ACBI3 视为验证了该概念的化合物，指出其设计由三元复合物的生物物理与结构研究引导，而非仅靠经验筛选。同一综述将其置于包含学术降解剂与多家制药公司项目的竞争格局中。更广义的文化意义在于 KRAS 从经典的不可成药靶点，转变为抑制剂、降解剂与联合策略并行开发的领域。这一转变如今已成为靶向蛋白降解课程与综述中的标准案例。^[2]

Availability and economics

• ACBI3 is not a commercial product and has no pricing, reimbursement or market landscape. Its availability is as a research tool supplied free of charge through the Boehringer Ingelheim opnMe portal. Any therapeutic product derived from the programme would require full IND-enabling work, including GMP production, extended in vivo efficacy and resistance testing beyond the reported 14-day regimens, formal PK/PD and toxicology assessment. Boehringer Ingelheim has not announced clinical development plans for the compound itself, and the partner ecosystem continues to explore alternative E3 ligases, lower molecular weight designs and nanoparticle or antibody-conjugate delivery to solve the parenteral dosing problem. Market projections for pan-KRAS degraders remain speculative until a clinical candidate is named.ACBI3 不是商业产品，没有定价、报销或市场格局，其可及性是作为研究工具通过勃林格殷格翰 opnMe 门户免费提供。该项目衍生的任何治疗产品都需要完整的 IND 支持性工作，包括 GMP 生产、超出已报告 14 天方案的在体延长疗效与耐药测试、正式 PK/PD 与毒理学评估。勃林格殷格翰尚未公布该化合物本身的临床开发计划，合作生态仍在探索替代 E3 连接酶、更低分子量设计以及纳米颗粒或抗体偶联递送，以解决肠外给药问题。在临床候选药物确定之前，泛 KRAS 降解剂的市场预测仍是推测性的。
• The commercial backdrop is the KRAS inhibitor market created by sotorasib and adagrasib, the first approved agents for a target that had defeated two decades of screening programmes. Those approvals validated KRAS as a drug target but left most patients without a mutation-matched option, which is the commercial opening for pan-mutant degraders. Analysts have noted that a pan-KRAS degrader with a convenient dosing schedule would address a larger population than any allele-specific inhibitor, but no such agent has entered the clinic. ACBI3's parenteral dosing profile keeps it on the research side of that boundary.商业背景是由（sotorasib）与（adagrasib）创造的 KRAS 抑制剂市场，二者是击败了二十年筛选项目的靶点首批获批药物。这些批准验证了 KRAS 作为药物靶点，但多数患者仍无匹配突变的选项，这正是泛突变降解剂的商业切口。分析人士指出，给药方便的泛 KRAS 降解剂将覆盖比任何等位基因特异性抑制剂更大的人群，但尚无此类药物进入临床。ACBI3 的肠外给药特征使其留在这一边界的研究一侧。
• For the research community the practical economics are unusually favourable: a compound that would normally be a closely held internal asset is available at no cost, with the negative control supplied alongside it. The main costs for users are the assay systems, since KRAS degradation requires cell lines with defined alleles and the proteomic readouts needed to confirm target removal. Companies in the field have followed with their own probe and programme disclosures, and the resulting openness has accelerated the whole degrader field. Whether that openness survives the move into proprietary development programmes remains to be seen.对研究界而言，实际经济条件异常有利：一种通常会被严加内部持有的化合物可免费获得，阴性对照随附提供。使用者的主要成本在于检测体系，因为 KRAS 降解需要定义等位基因的细胞系与确认靶点移除所需的蛋白质组学读数。业内公司随后也公布了自己的探针与项目信息，由此带来的开放加速了整个降解剂领域。这种开放性能否在转入专有开发项目后存续，仍待观察。